These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
206 related articles for article (PubMed ID: 22507556)
1. Study of CCN3 (NOV) and DDR1 in normal melanocytes and vitiligo skin. Ricard AS; Pain C; Daubos A; Ezzedine K; Lamrissi-Garcia I; Bibeyran A; Guyonnet-Dupérat V; Taieb A; Cario-André M Exp Dermatol; 2012 Jun; 21(6):411-6. PubMed ID: 22507556 [TBL] [Abstract][Full Text] [Related]
2. CCN3 controls 3D spatial localization of melanocytes in the human skin through DDR1. Fukunaga-Kalabis M; Martinez G; Liu ZJ; Kalabis J; Mrass P; Weninger W; Firth SM; Planque N; Perbal B; Herlyn M J Cell Biol; 2006 Nov; 175(4):563-9. PubMed ID: 17101694 [TBL] [Abstract][Full Text] [Related]
3. Discoidin domain receptor-1 as a player in impairment of melanocytes adhesion process in vitiligo. Elgarhy LH; Abdullatif A; Abdelazim R; El-Desouky KI G Ital Dermatol Venereol; 2016 Oct; 151(5):473-9. PubMed ID: 26091274 [TBL] [Abstract][Full Text] [Related]
4. Polymorphism of the E-cadherin gene CDH1 is associated with susceptibility to vitiligo. Tarlé RG; Silva de Castro CC; do Nascimento LM; Mira MT Exp Dermatol; 2015 Apr; 24(4):300-2. PubMed ID: 25613741 [TBL] [Abstract][Full Text] [Related]
5. Reduced immunohistochemical expression of CCN3 in vitiligo. Faria AR; Jung JE; Silva de Catro CC; de Noronha L Indian J Dermatol Venereol Leprol; 2018; 84(5):558-562. PubMed ID: 29998862 [TBL] [Abstract][Full Text] [Related]
6. Genetic variants of the DDR1 gene are associated with vitiligo in two independent Brazilian population samples. Silva de Castro CC; do Nascimento LM; Walker G; Werneck RI; Nogoceke E; Mira MT J Invest Dermatol; 2010 Jul; 130(7):1813-8. PubMed ID: 20182441 [TBL] [Abstract][Full Text] [Related]
7. Dysregulation of CCN3 (NOV) expression in the epidermis of systemic sclerosis patients with pigmentary changes. Henrot P; Pain C; Taïeb A; Truchetet ME; Cario M Pigment Cell Melanoma Res; 2020 Nov; 33(6):895-898. PubMed ID: 32633087 [TBL] [Abstract][Full Text] [Related]
8. Aberrant expression of complement regulatory proteins, membrane cofactor protein and decay accelerating factor, in the involved epidermis of patients with vitiligo. van den Wijngaard RM; Asghar SS; Pijnenborg AC; Tigges AJ; Westerhof W; Das PK Br J Dermatol; 2002 Jan; 146(1):80-7. PubMed ID: 11841370 [TBL] [Abstract][Full Text] [Related]
9. Low-energy helium-neon laser induces melanocyte proliferation via interaction with type IV collagen: visible light as a therapeutic option for vitiligo. Lan CC; Wu CS; Chiou MH; Chiang TY; Yu HS Br J Dermatol; 2009 Aug; 161(2):273-80. PubMed ID: 19438447 [TBL] [Abstract][Full Text] [Related]
10. The melanocytorrhagic hypothesis of vitiligo tested on pigmented, stressed, reconstructed epidermis. Cario-André M; Pain C; Gauthier Y; Taïeb A Pigment Cell Res; 2007 Oct; 20(5):385-93. PubMed ID: 17850512 [TBL] [Abstract][Full Text] [Related]
11. Aberrant ETS-1 signalling impedes the expression of cell adhesion molecules and matrix metalloproteinases in non-segmental vitiligo. Srivastava N; Bishnoi A; Mehta S; Rani S; Kumar R; Bhardwaj S; Sendhil Kumaran M; Keshavamurthy V; Gupta S; Parsad D Exp Dermatol; 2020 Jun; 29(6):539-547. PubMed ID: 32350934 [TBL] [Abstract][Full Text] [Related]
12. New insights into the pathogenesis of vitiligo: imbalance of epidermal cytokines at sites of lesions. Moretti S; Spallanzani A; Amato L; Hautmann G; Gallerani I; Fabiani M; Fabbri P Pigment Cell Res; 2002 Apr; 15(2):87-92. PubMed ID: 11936274 [TBL] [Abstract][Full Text] [Related]
13. Immunolocalization of tenascin-C in vitiligo. Abdou AG; Maraee AH; Shoeib MA; Elbana R Appl Immunohistochem Mol Morphol; 2012 Oct; 20(5):501-11. PubMed ID: 22495383 [TBL] [Abstract][Full Text] [Related]
14. CDH1 and DDR1 common variants confer risk to vitiligo and autoimmune comorbidities. Almasi-Nasrabadi M; Amoli MM; Robati RM; Rajabi F; Ghalamkarpour F; Gauthier Y Gene; 2019 Jun; 700():17-22. PubMed ID: 30890477 [TBL] [Abstract][Full Text] [Related]
15. Tenascin is overexpressed in vitiligo lesional skin and inhibits melanocyte adhesion. Le Poole IC; van den Wijngaard RM; Westerhof W; Das PK Br J Dermatol; 1997 Aug; 137(2):171-8. PubMed ID: 9292062 [TBL] [Abstract][Full Text] [Related]
16. Epidermal hydrogen peroxide is not increased in lesional and non-lesional skin of vitiligo. Zailaie MZ Arch Dermatol Res; 2017 Jan; 309(1):31-42. PubMed ID: 27783153 [TBL] [Abstract][Full Text] [Related]
17. Downregulation of CCN3 expression as a potential mechanism for melanoma progression. Fukunaga-Kalabis M; Martinez G; Telson SM; Liu ZJ; Balint K; Juhasz I; Elder DE; Perbal B; Herlyn M Oncogene; 2008 Apr; 27(18):2552-60. PubMed ID: 17968313 [TBL] [Abstract][Full Text] [Related]
18. Altered E-Cadherin Levels and Distribution in Melanocytes Precede Clinical Manifestations of Vitiligo. Wagner RY; Luciani F; Cario-André M; Rubod A; Petit V; Benzekri L; Ezzedine K; Lepreux S; Steingrimsson E; Taieb A; Gauthier Y; Larue L; Delmas V J Invest Dermatol; 2015 Jul; 135(7):1810-1819. PubMed ID: 25634357 [TBL] [Abstract][Full Text] [Related]
19. Expression of discoidin domain receptor 1 and E-cadherin in epidermis affects melanocyte behavior in rhododendrol-induced leukoderma mouse model. Abe Y; Hozumi Y; Okamura K; Suzuki T J Dermatol; 2020 Nov; 47(11):1330-1334. PubMed ID: 32770866 [TBL] [Abstract][Full Text] [Related]
20. Type-1 cytokines regulate MMP-9 production and E-cadherin disruption to promote melanocyte loss in vitiligo. Boukhedouni N; Martins C; Darrigade AS; Drullion C; Rambert J; Barrault C; Garnier J; Jacquemin C; Thiolat D; Lucchese F; Morel F; Ezzedine K; Taieb A; Bernard FX; Seneschal J; Boniface K JCI Insight; 2020 Jun; 5(11):. PubMed ID: 32369451 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]